Clinical trials: Hematological Disease
Chronic Myelomonocytic Leukemia, Leukemia
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
This study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study drug (ruxolitinib) can improve outcomes of patients with CMML.
- Trial name
- NCT03722407
- Testing
- Ruxolitinib
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia, Myeloid, Acute
Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML."
The goal of this clinical trial is to learn if Revumenib in combination with Fludarabine and Cytarabine can treat children with NUP98-rearranged relapsed or refractory Acute Myeloid Leukemia.
- Trial name
- NCT07686107
- Testing
- Revumenib, Fludarabine, Cytarabine (Ara-C)
- Volunteers
- 24 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Essential Thrombocythaemia
A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients
The primary objective of this study is to assess the efficacy of ropeginterferon alfa-2b in patients with ET who need cytoreductive treatment but are intolerant or refractory to, and/or ineligible for cytoreductive treatments…
- Trial name
- NCT06514807
- Testing
- Ropeginterferon alfa-2b (BESREMi®)
- Where
- 36 sites in Austria, Czechia and 8 more
- Volunteers
- 117 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Multiple Myeloma
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize…
- Trial name
- NCT04108195
- Testing
- Daratumumab, Talquetamab, Teclistamab
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 290 people
- Sponsor
- Janssen Research & Development, LLC
Acute Myeloid Leukemia
Oral Azacitidine Maintenance Post-CPX 351
Approximately 10% of patient develop AML after chemotherapy or radiation for unrelated disease (t-AML) and 20% have AML with an antecedent hematologic disorder (AML-MRC).
- Trial name
- ORAZ-351 (NCT06349239)
- Testing
- No intervention
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Liposuction, Bruising
Bridging the Healing Gap: A Single-Blind Clinical Trial Assessing the Efficacy of Carboxy-gel in Reducing Bruising and Pain Post-Liposuction
The goal of this clinical trial is to evaluate if CO2 Lift reduces bruising and pain after Liposuction. The study also aims to explore changes in patient satisfaction.
- Conditions
- Liposuction, Bruising, Inflammation, Pain, Postoperative
- Trial name
- CO2L001 (NCT06791577)
- Testing
- Carboxytherapy
- Where
- 3 sites in Brazil, Colombia and 1 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Total Definer Research Group
Myelodysplasia
Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents
Patients with low-risk MDS verifying the eligibility criteria may be included in the study.
- Trial name
- LODEFI (NCT03387475)
- Testing
- Deferasirox
- Where
- France
- Volunteers
- 39 people
- Sponsor
- University Hospital, Grenoble
Sickle Cell Trait, Sickle Cell Disease
Blood Sampling for Research Related to Sickle Cell Disease
This study will collect representative blood samples from healthy children and adults and from children and adults who have unique red blood cell features that are related to sickle cell disease.
- Conditions
- Sickle Cell Trait, Sickle Cell Disease, Sickle Cell Anemia
- Trial name
- NCT00542230
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Multiple Myeloma, Amyloidosis
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG-2575 in combination with Pd/DRd in patients with relapsed/refractory (RR) multiple myeloma (MM).
- Trial name
- NCT04942067
- Testing
- APG-2575+ Pd, APG-2575 + DRd
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- Ascentage Pharma Group Inc.
Iron Deficiency Anemia, Iron Overload
Iron Supplementation and Side Effects
The objective of this study is to examine patient-reported gastrointestinal side effects, as well as iron status indicators, inflammatory markers and oxidative stress following administration of ferrous sulfate and iron-enriched…
- Trial name
- NCT04018300
- Testing
- Ferrous sulfate, Aspiron
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Iowa State University
Acute Myeloid Leukemia, Myeloproliferative Neoplasm
Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant
Intensive conditioning regimens used in allogeneic hematopoietic cell transplant (HCT) help to eliminate hematologic tumors and reduce the risk of relapse, but are also characterized by high toxicity.
- Conditions
- Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT07634536
- Testing
- VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Anaemia, Myocardial Ischaemia, Fractured Neck of Femur
Cardiac Injury and Anaemia Following Surgery for Fractured Neck of Femur: An Observational Study Study Protocol: Cardiac Injury and Anaemia Following Surgery for Fractured Neck of Femur
Blood transfusion is an expensive and finite resource and optimum transfusion threshold in surgical patients is yet to be defined.
- Trial name
- NCT02969811
- Volunteers
- 47 people
- Sponsor
- NHS Lothian
Relapsed or Refractory Multiple Myeloma
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM).
- Trial name
- NCT06375044
- Testing
- SIM0500
- Where
- 16 sites in United States, China
- Volunteers
- 130 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Lymphoma
Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00003356
- Testing
- aldesleukin, rituximab
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of Rochester
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT02892695
- Testing
- anti-CD19 CAR-NK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Leukemia
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia
Phase I trial to study the effectiveness of PSC-833 plus etoposide and mitoxantrone in treating children who have refractory or relapsed acute leukemia.
- Trial name
- NCT00002912
- Testing
- etoposide, mitoxantrone hydrochloride, valspodar
- Where
- 55 sites in United States, Australia and 1 more
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Hemophilia A, Hemophilia B
Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study
This is a multi-center, international study designed to collect clinical, genetic and quality of life information on females with hemophilia, an inherited bleeding disorder.
- Trial name
- NCT00936312
- Where
- 11 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Weill Medical College of Cornell University
Hematological Malignancies, Leukemia
STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors
The purpose of this study is to determine the safety, toxicity and patient tolerance of STA-5312 administered intravenously to patients with relapsed or refractory hematological malignancies and patients with solid tumors.
- Conditions
- Hematological Malignancies, Leukemia, Lymphoma, Metastatic or Unresectable Solid Tumors
- Trial name
- NCT00088101
- Testing
- STA-5312
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- Synta Pharmaceuticals Corp.
Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
The purpose of this study is to provide expanded access to gilteritinib (ASP2215) for patients with FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed or refractory acute myeloid leukemia (AML) or with FLT3-mutated AML in…
- Trial name
- NCT03409081
- Testing
- gilteritinib
- Where
- 6 sites in Australia, Italy and 1 more
- Sponsor
- Astellas Pharma Global Development, Inc.
Acute Lymphoblastic Leukemia, Adult B-Cell
Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia
The GRAALL-QUEST study is a Phase 2 study nested in the GRAALL-2014/B study (NCT02617004). The GRAALL-QUEST study evaluates the safety and the efficacy of blinatumomab-containing consolidation and maintenance therapy in patients…
- Trial name
- GRAALL-QUEST (NCT03709719)
- Testing
- Blinatumomab Injection
- Where
- France
- Volunteers
- 95 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.